Evidence map›Paper›PMID 42418861›Full record

ArticleStem cell research2026

Generation of three induced pluripotent stem cell lines from an immune checkpoint inhibitor-induced myocarditis patient and controls.

Yin Sun, Maria Rosaria Vitale, Anna P Hnatiuk, Noah S Wagner, Shuai Sun, Xiaochun Yang, Lu Liu, Shaheen Khatua, Hiranya Amritavalli Sundar, Harrison Chou and 7 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Stem cell research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Yin SunStanford Cardiovascular Institute, Stanford University School of Medicine, Stanford, CA 94305, USA.
Maria Rosaria VitaleStanford Cardiovascular Institute, Stanford University School of Medicine, Stanford, CA 94305, USA.
Anna P HnatiukStanford Cardiovascular Institute, Stanford University School of Medicine, Stanford, CA 94305, USA.
Noah S WagnerStanford Cardiovascular Institute, Stanford University School of Medicine, Stanford, CA 94305, USA.
Shuai SunStanford Cardiovascular Institute, Stanford University School of Medicine, Stanford, CA 94305, USA; Department of Medicine, Division of Cardiovascular Medicine, Stanford University School of Medicine, Stanford, CA 94305, USA.
Xiaochun YangStanford Cardiovascular Institute, Stanford University School of Medicine, Stanford, CA 94305, USA.
Lu LiuStanford Cardiovascular Institute, Stanford University School of Medicine, Stanford, CA 94305, USA.
Shaheen KhatuaStanford Cardiovascular Institute, Stanford University School of Medicine, Stanford, CA 94305, USA.
Hiranya Amritavalli SundarStanford Cardiovascular Institute, Stanford University School of Medicine, Stanford, CA 94305, USA.
Harrison ChouStanford Cardiovascular Institute, Stanford University School of Medicine, Stanford, CA 94305, USA.
Yuhsin Vivian HuangStanford Cardiovascular Institute, Stanford University School of Medicine, Stanford, CA 94305, USA; Weill Cornell Medicine, New York, NY 10021, USA.
Sarah WalianyMass General Brigham Cancer Institute, Boston, MA 02114, USA.
Yan ZhugeStanford Cardiovascular Institute, Stanford University School of Medicine, Stanford, CA 94305, USA.
Ronald WittelesDepartment of Medicine, Division of Cardiovascular Medicine, Stanford University School of Medicine, Stanford, CA 94305, USA.
Mark MercolaStanford Cardiovascular Institute, Stanford University School of Medicine, Stanford, CA 94305, USA; Department of Medicine, Division of Cardiovascular Medicine, Stanford University School of Medicine, Stanford, CA 94305, USA.
Joseph C WuStanford Cardiovascular Institute, Stanford University School of Medicine, Stanford, CA 94305, USA; Department of Medicine, Division of Cardiovascular Medicine, Stanford University School of Medicine, Stanford, CA 94305, USA.
Han ZhuStanford Cardiovascular Institute, Stanford University School of Medicine, Stanford, CA 94305, USA; Department of Medicine, Division of Cardiovascular Medicine, Stanford University School of Medicine, Stanford, CA 94305, USA. Electronic address: hanzhu@stanford.edu.

Funding

Advancing Personalized Cardiac Organoids - Converging In Vitro, In Chemico, and In Silico ModelsUM1TR006031 · NCATS · STANFORD UNIVERSITY · PI Afshin Beheshti, Sarah C Heilshorn · 2026 to 2026
$3.1M
Targeting the genotype to phenotype link in HCM as a therapeutic strategyR01HL152055 · NHLBI · STANFORD UNIVERSITY · PI MERCOLA, MARK · 2021 to 2024
$2.3M
Investigating CXCR3 Blockade as Precision Therapy for Cardiac Sarcoidosis using Single-Cell Multi-omics and TCR PhenotypingR01HL174432 · NHLBI · STANFORD UNIVERSITY · PI Han Zhu · 2024 to 2026
$2.2M
A Targeted Approach to Treat Immunotherapy-Induced Myocarditis with CXCR3 BlockadeR01HL177581 · NHLBI · STANFORD UNIVERSITY · PI Han Zhu · 2025 to 2026
$1.5M
Unraveling Proteasome Inhibitor-Induced Cardiovascular Toxicity through Integrative MultiomicsR01HL176822 · NHLBI · STANFORD UNIVERSITY · PI MARK MERCOLA, Joseph C. Wu · 2025 to 2026
$1.4M
Identification of Causal T-Cell Mechanisms in Immune Checkpoint Inhibitor Induced MyocarditisK08HL161405 · NHLBI · STANFORD UNIVERSITY · PI Han Zhu · 2022 to 2026
$880k
Defining kinase interaction pathways to enhance anti-cancer efficacy and minimize associated morbidities of kinase inhibitor drugs.K99CA279895 · NCI · STANFORD UNIVERSITY · PI HNATIUK HNATIUK, ANNA PAVLOVNA · 2023 to 2024
$276k
CXCL9/10 Macrophage Induced CXCR3+ T-cell Recruitment to the Heart Contributes to Immunotherapy MyocarditisR03HL173146 · NHLBI · STANFORD UNIVERSITY · PI ZHU, HAN · 2024 to 2025
$236k
NCATS NIH HHS UM1 TR006031NCI NIH HHS K99 CA279895NHLBI NIH HHS K08 HL161405NHLBI NIH HHS R01 HL152055NHLBI NIH HHS R01 HL174432NHLBI NIH HHS R01 HL176822NHLBI NIH HHS R01 HL177581NHLBI NIH HHS R03 HL173146
6 · The paper itself

Abstract

Immune checkpoint inhibitor-associated myocarditis (ICIM) is an uncommon but potentially fatal inflammatory heart disease triggered by cancer immunotherapy, with up to 40% mortality. The underlying mechanisms are still elusive, partly due to the lack of appropriate human disease models. Here, we report the generation of three induced pluripotent stem cell (iPSC) lines derived from an ICIM patient, an ICI-treated patient without myocarditis, and a healthy donor. These lines exhibit typical pluripotent stem cell morphology, express pluripotency markers, maintain normal karyotypes, and differentiate into derivatives of the three germ layers, providing a valuable platform for mechanistic studies and therapeutic discovery.

Indexed as

Immune Checkpoint InhibitorsInduced Pluripotent Stem CellsMyocarditisCell DifferentiationCell LineHumansMaleImmune Checkpoint Inhibitors

Identifiers

PMID42418861
PMCPMC13592351

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.